Pharma Stocks
-
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN +0.75%), reported the sale of 5,222 ordinary shares for a…
Read More » -
Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE. Alnylam…
Read More » -
Stocks to Watch for June 15: Vedanta, Aurobindo Pharma, JSW Energy, Dr Reddy’s and more
From Vedanta’s demerged entities market debut to JSW Energy’s wholly owned subsidiary JSW Neo Energy Ltd commissioning the full 150…
Read More » -
Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation
Ascentage Pharma Group International (SEHK:6855) drew fresh market attention after presenting new ASCO 2026 data on olverembatinib in chronic myeloid…
Read More » -
Astellas Pharma (TSE:4503) Stock Valuation After KRAS Trial Progress And AI Overhaul
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply…
Read More » -
Pharma, tech, EVs cheer FY27 budget as tobacco, steel count the cost
The proposed national budget for FY2026–27 has set the stage for a sweeping transformation of the country’s capital market, with…
Read More » -
NewAmsterdam Pharma (NAMS) Stock Valuation After New Obicetrapib Phase 3 And PREVAIL Trial Updates
Clinical data on obicetrapib puts NewAmsterdam Pharma in focus NewAmsterdam Pharma (NasdaqGM:NAMS) has drawn fresh attention after reporting Phase 3…
Read More » -
Teva’s Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Teva Pharmaceutical Industries (TEVA +0.20%) has clawed back from the brink like few drugmakers have. After a long stretch of…
Read More » -
Is Zasocitinib’s Phase 3 Beat And New Shelf Filing Altering The Investment Case For Takeda Pharmaceutical (TSE:4502)?
Earlier this month, Takeda Pharmaceutical announced that its oral TYK2 inhibitor zasocitinib delivered statistically superior Phase 3 results versus deucravacitinib…
Read More » -
Chugai Pharmaceutical (TSE:4519) Stock Valuation After Recent Share Price Weakness
Chugai Pharmaceutical (TSE:4519) has drawn fresh attention after recent share price moves, with the stock down about 4.5% over the…
Read More »